

Nai-Kong V Cheung

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/633247/publications.pdf>

Version: 2024-02-01

249
papers

13,025
citations

20817

60
h-index

32842

100
g-index

258
all docs

258
docs citations

258
times ranked

12324
citing authors

#	ARTICLE	IF	CITATIONS
1	Influence of Fc Modifications and IgG Subclass on Biodistribution of Humanized Antibodies Targeting L1CAM. <i>Journal of Nuclear Medicine</i> , 2022, 63, 629-636.	5.0	5
2	KMT2A-MAML2 rearrangement emerged and regressed during neuroblastoma therapy without leukemia after 12.8-year follow-up. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29344.	1.5	1
3	Expression Analysis of GD2 by Immunohistochemistry in Invasive Breast Carcinoma: Clinical and Pathologic Correlation. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2022, 30, 113-118.	1.2	3
4	Intraperitoneal Pretargeted Radioimmunotherapy for Colorectal Peritoneal Carcinomatosis. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 125-137.	4.1	5
5	Overcoming tumor heterogeneity by ex vivo arming of T cells using multiple bispecific antibodies. , 2022, 10, e003771.		4
6	Bone Marrow Surveillance of Pediatric Cancer Survivors Identifies Clones that Predict Therapy-Related Leukemia. <i>Clinical Cancer Research</i> , 2022, 28, 1614-1627.	7.0	4
7	Ganglioside GD2 Enhances the Malignant Phenotypes of Melanoma Cells by Cooperating with Integrins. <i>International Journal of Molecular Sciences</i> , 2022, 23, 423.	4.1	16
8	Bispecific antibodies for the treatment of neuroblastoma. , 2022, 237, 108241.		3
9	A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted Radioimmunotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 532-541.	7.0	19
10	IntraOmmaya compartmental radioimmunotherapy using 131I-omburtamab pharmacokinetic modeling to optimize therapeutic index. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1166-1177.	6.4	9
11	Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma With Prior Disease Progression. <i>Journal of Clinical Oncology</i> , 2021, 39, 215-226.	1.6	60
12	Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors. <i>Nature Cancer</i> , 2021, 2, 357-365.	13.2	74
13	Differential Impact of ALK Mutations in Neuroblastoma. <i>JCO Precision Oncology</i> , 2021, 5, 492-500.	3.0	6
14	Engineered Cells as a Test Platform for Radiohaptens in Pretargeted Imaging and Radioimmunotherapy Applications. <i>Bioconjugate Chemistry</i> , 2021, 32, 649-654.	3.6	6
15	Potent antitumor effect of T cells armed with anti-GD2 bispecific antibody. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28971.	1.5	8
16	Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release. , 2021, 9, e002222.		24
17	T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia. , 2021, 9, e002509.		5
18	Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response. <i>Journal of Hematology and Oncology</i> , 2021, 14, 142.	17.0	21

#	ARTICLE	IF	CITATIONS
19	Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy. , 2021, 9, e003114.		23
20	A novel multimeric IL15/IL15R α -Fc complex to enhance cancer immunotherapy. <i>Onc Immunology</i> , 2021, 10, 1893500.	4.6	9
21	Human Cytomegalovirus Infection Promotes Expansion of a Functionally Superior Cytoplasmic CD3+ NK Cell Subset with a Bcl11b-Regulated T Cell Signature. <i>Journal of Immunology</i> , 2021, 207, 2534-2544.	0.8	4
22	Reciprocal impacts of telomerase activity and ADRN/MES differentiation state in neuroblastoma tumor biology. <i>Communications Biology</i> , 2021, 4, 1315.	4.4	2
23	Immunotherapy and Radioimmunotherapy for Desmoplastic Small Round Cell Tumor. <i>Frontiers in Oncology</i> , 2021, 11, 772862.	2.8	8
24	Phase I Trial of Oral Yeast-Derived β -D-Glucan to Enhance Anti-GD2 Immunotherapy of Resistant High-Risk Neuroblastoma. <i>Cancers</i> , 2021, 13, 6265.	3.7	6
25	Therapeutic Antibodies and Immunologic Conjugates. , 2020, , 486-499.e8.		2
26	An N-Acetylgalactosamino Dendron-Clearing Agent for High-Therapeutic-Index DOTA-Hapten Pretargeted Radioimmunotherapy. <i>Bioconjugate Chemistry</i> , 2020, 31, 501-506.	3.6	16
27	Characterizing and classifying neuroendocrine neoplasms through microRNA sequencing and data mining. <i>NAR Cancer</i> , 2020, 2, zcaa009.	3.1	11
28	Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations. <i>Nature Communications</i> , 2020, 11, 5183.	12.8	87
29	Alpha radioimmunotherapy using ^{225}Ac -proteus-DOTA for solid tumors - safety at curative doses. <i>Theranostics</i> , 2020, 10, 11359-11375.	10.0	26
30	Cancer immunotherapy via targeted TGF- β signalling blockade in TH cells. <i>Nature</i> , 2020, 587, 121-125.	27.8	157
31	Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies. , 2020, 8, e001626.		6
32	B7H3-Directed Intraperitoneal Radioimmunotherapy With Radioiodinated Omburtamab for Desmoplastic Small Round Cell Tumor and Other Peritoneal Tumors: Results of a Phase I Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 4283-4291.	1.6	40
33	Editorial: Bispecific Antibodies for T-Cell Based Immunotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 628005.	2.8	3
34	GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma. <i>Journal of Hematology and Oncology</i> , 2020, 13, 172.	17.0	43
35	Interdomain spacing and spatial configuration drive the potency of IgG-[L]-scFv T cell bispecific antibodies. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	54
36	Targets and Antibody Formats for Immunotherapy of Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 1836-1848.	1.6	74

#	ARTICLE	IF	CITATIONS
37	Reduced-dose craniospinal irradiation for central nervous system relapsed neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28364.	1.5	7
38	Immunotherapy of Pediatric Solid Tumors: Treatments at a Crossroads, with an Emphasis on Antibodies. <i>Cancer Immunology Research</i> , 2020, 8, 161-166.	3.4	48
39	Biodistribution and Dosimetry of Intraventricularly Administered ¹²⁴ I-Omburtamab in Patients with Metastatic Leptomeningeal Tumors. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1794-1801.	5.0	29
40	Assessment of pulmonary outcomes, exercise capacity, and longitudinal changes in lung function in pediatric survivors of high-risk neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27960.	1.5	5
41	Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma. <i>Frontiers in Oncology</i> , 2019, 9, 537.	2.8	21
42	ATRX In-Frame Fusion Neuroblastoma Is Sensitive to EZH2 Inhibition via Modulation of Neuronal Gene Signatures. <i>Cancer Cell</i> , 2019, 36, 512-527.e9.	16.8	44
43	Telomere Trimming and DNA Damage as Signatures of High Risk Neuroblastoma. <i>Neoplasia</i> , 2019, 21, 689-701.	5.3	11
44	Reduced-Dose Radiation Therapy to the Primary Site is Effective for High-Risk Neuroblastoma: Results From a Prospective Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 409-414.	0.8	13
45	Targeted radioimmunotherapy for embryonal tumor with multilayered rosettes. <i>Journal of Neuro-Oncology</i> , 2019, 143, 101-106.	2.9	17
46	Silencing Fc Domains in T cell-Engaging Bispecific Antibodies Improves T-cell Trafficking and Antitumor Potency. <i>Cancer Immunology Research</i> , 2019, 7, 2013-2024.	3.4	37
47	Phase I study of OKT3 x hu3F8 bispecific antibody (GD2Bi) armed T cells (GD2BATs) in GD2-positive tumors.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2533-2533.	1.6	11
48	Dose-escalation is needed for gross disease in high-risk neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27009.	1.5	17
49	Treatment and outcome of adult-onset neuroblastoma. <i>International Journal of Cancer</i> , 2018, 143, 1249-1258.	5.1	23
50	Radiation Therapy to Sites of Metastatic Disease as Part of Consolidation in High-Risk Neuroblastoma: Can Long-term Control Be Achieved?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1204-1209.	0.8	19
51	A phase II study of radioimmunotherapy with intraventricular ¹³¹ I-3F8 for medulloblastoma. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26754.	1.5	46
52	Genotyping Natural Killer Immune Checkpoints to Discover Biomarkers of Response. <i>Clinical Cancer Research</i> , 2018, 24, 3-5.	7.0	6
53	Targeting Intracellular Antigens with pMHC-Binding Antibodies: A Phage Display Approach. <i>Methods in Molecular Biology</i> , 2018, 1701, 255-269.	0.9	0
54	Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma. <i>Theranostics</i> , 2018, 8, 5106-5125.	10.0	32

#	ARTICLE	IF	CITATIONS
55	TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies. JCI Insight, 2018, 3, .	5.0	34
56	Humanized 3F8 Anti-GD2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma. JAMA Oncology, 2018, 4, 1729.	7.1	86
57	A potent tetravalent T-cell-engaging bispecific antibody against CD33 in acute myeloid leukemia. Blood Advances, 2018, 2, 1250-1258.	5.2	34
58	Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I study. Oncoimmunology, 2018, 7, e1461305.	4.6	49
59	Development of a Tetravalent Anti-GPA33/Anti-CD3 Bispecific Antibody for Colorectal Cancers. Molecular Cancer Therapeutics, 2018, 17, 2164-2175.	4.1	30
60	Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase I trial. Lancet Oncology, The, 2018, 19, 1040-1050.	10.7	201
61	Early Detection and Molecular Characterization of Therapy-Related Leukemia in Children Reveals Patterns of Disease Transformation and Guides Future Surveillance Protocols. Blood, 2018, 132, 291-291.	1.4	0
62	Exceptionally Potent Cytotherapy Using T Cells Armed with Novel Tetravalent Recombinant Bispecific Antibodies Specific for GD2 and HER2. Blood, 2018, 132, 4536-4536.	1.4	1
63	Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study. Pediatric Blood and Cancer, 2017, 64, e26448.	1.5	44
64	Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies. Cancer Letters, 2017, 399, 44-52.	7.2	44
65	Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies. Cancer Treatment Reviews, 2017, 58, 22-33.	7.7	76
66	Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2. Oncoimmunology, 2017, 6, e1320625.	4.6	31
67	Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody. Oncoimmunology, 2017, 6, e1267891.	4.6	66
68	Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer. Journal of Nuclear Medicine, 2017, 58, 1735-1742.	5.0	36
69	Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival. Oncoimmunology, 2017, 6, e1358331.	4.6	25
70	A phase I/II trial targeting the PI3k/Akt pathway using perifosine: long-term progression-free survival of patients with resistant neuroblastoma. International Journal of Cancer, 2017, 140, 480-484.	5.1	41
71	A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors. PLoS ONE, 2017, 12, e0178593.	2.5	38
72	MYCN-amplified stage 2/3 neuroblastoma: excellent survival in the era of anti-GD2 immunotherapy. Oncotarget, 2017, 8, 95293-95302.	1.8	10

#	ARTICLE	IF	CITATIONS
73	Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1780-1785.	1.5	106
74	Temporal stability and molecular persistence of the bone marrow plasma cell antibody repertoire. <i>Nature Communications</i> , 2016, 7, 13838.	12.8	11
75	Local Control With 21-Gy Radiation Therapy for High-Risk Neuroblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 393-400.	0.8	36
76	Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumors. <i>Onc Immunology</i> , 2016, 5, e1168557.	4.6	30
77	<i>KIR3DL1</i> Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 2443-2451.	1.6	73
78	Antitumor Efficacy of Anti-GD2 IgG1 Is Enhanced by Fc Glyco-Engineering. <i>Cancer Immunology Research</i> , 2016, 4, 631-638.	3.4	18
79	Arsenic Trioxide as a Radiation Sensitizer for ¹³¹ I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study. <i>Journal of Nuclear Medicine</i> , 2016, 57, 231-237.	5.0	17
80	Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity ⁸⁶ Y- or ¹⁷⁷ Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 925-937.	6.4	38
81	Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin. <i>Oncotarget</i> , 2016, 7, 4155-4166.	1.8	51
82	Antibody induced pain in children: An opportunity to study pain mechanism, IgG design and analgesics. <i>Pediatric Blood and Cancer</i> , 2015, 62, 186-187.	1.5	0
83	A dual-specific anti-IGF1/IGF2 human monoclonal antibody alone and in combination with temsirolimus for therapy of neuroblastoma. <i>International Journal of Cancer</i> , 2015, 137, 2243-2252.	5.1	19
84	Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1326-1336.	1.5	10
85	Immunotherapy of Childhood Sarcomas. <i>Frontiers in Oncology</i> , 2015, 5, 181.	2.8	54
86	Radioimmunotherapy of human tumours. <i>Nature Reviews Cancer</i> , 2015, 15, 347-360.	28.4	382
87	Low incidence of radionecrosis in children treated with conventional radiation therapy and intrathecal radioimmunotherapy. <i>Journal of Neuro-Oncology</i> , 2015, 123, 245-249.	2.9	22
88	Humanized Affinity-matured Monoclonal Antibody 8H9 Has Potent Antitumor Activity and Binds to FG Loop of Tumor Antigen B7-H3. <i>Journal of Biological Chemistry</i> , 2015, 290, 30018-30029.	3.4	84
89	Bone Marrow Minimal Residual Disease Was an Early Response Marker and a Consistent Independent Predictor of Survival After Anti-GD2 Immunotherapy. <i>Journal of Clinical Oncology</i> , 2015, 33, 755-763.	1.6	40
90	Retargeting T Cells to GD2 Pentasaccharide on Human Tumors Using Bispecific Humanized Antibody. <i>Cancer Immunology Research</i> , 2015, 3, 266-277.	3.4	74

#	ARTICLE	IF	CITATIONS
91	Disialoganglioside GD2 as a therapeutic target for human diseases. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 349-362.	3.4	131
92	Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody. <i>Oncolmunology</i> , 2015, 4, e989776.	4.6	25
93	Osteochondroma in long-term survivors of high-risk neuroblastoma. <i>Cancer</i> , 2015, 121, 2090-2096.	4.1	15
94	Alteration of Electrostatic Surface Potential Enhances Affinity and Tumor Killing Properties of Anti-ganglioside GD2 Monoclonal Antibody hu3F8. <i>Journal of Biological Chemistry</i> , 2015, 290, 13017-13027.	3.4	29
95	Desmoplastic small round cell tumor 20 years after its discovery. <i>Future Oncology</i> , 2015, 11, 1071-1081.	2.4	39
96	Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-G _{D2} immunotherapy and isotretinoin: a prospective Phase II study. <i>Oncolmunology</i> , 2015, 4, e1016704.	4.6	52
97	A distinct gene expression signature characterizes human neuroblastoma cancer stem cells. <i>Stem Cell Research</i> , 2015, 15, 419-426.	0.7	53
98	Anti-proliferative and pro-apoptotic activity of GD2 ganglioside-specific monoclonal antibody 3F8 in human melanoma cells. <i>Oncolmunology</i> , 2015, 4, e1023975.	4.6	33
99	Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy. <i>International Journal of Cancer</i> , 2015, 136, 476-486.	5.1	38
100	Phase I Trial of a Bivalent Gangliosides Vaccine in Combination with β -Glucan for High-Risk Neuroblastoma in Second or Later Remission. <i>Clinical Cancer Research</i> , 2014, 20, 1375-1382.	7.0	118
101	Structure Based Refinement of a Humanized Monoclonal Antibody That Targets Tumor Antigen Disialoganglioside GD2. <i>Frontiers in Immunology</i> , 2014, 5, 372.	4.8	17
102	Key role for myeloid cells: Phase II results of anti-G _{D2} antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma. <i>International Journal of Cancer</i> , 2014, 135, 2199-2205.	5.1	77
103	Imaging the Norepinephrine Transporter in Neuroblastoma: A Comparison of [18F]-MFBG and 123I-MIBG. <i>Clinical Cancer Research</i> , 2014, 20, 2182-2191.	7.0	61
104	Preclinical Evaluation of Multistep Targeting of Disialoganglioside GD2 Using an IgG-scFv Bispecific Antibody with High Affinity for GD2 and DOTA Metal Complex. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 1803-1812.	4.1	52
105	Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy. <i>FEBS Letters</i> , 2014, 588, 288-297.	2.8	115
106	GD2-Targeted Immunotherapy and Radioimmunotherapy. <i>Seminars in Oncology</i> , 2014, 41, 589-612.	2.2	69
107	The potential of theragnostic 124I-8H9 convection-enhanced delivery in diffuse intrinsic pontine glioma. <i>Neuro-Oncology</i> , 2014, 16, 800-806.	1.2	38
108	Identification of plasma Complement C3 as a potential biomarker for neuroblastoma using a quantitative proteomic approach. <i>Journal of Proteomics</i> , 2014, 96, 1-12.	2.4	19

#	ARTICLE	IF	CITATIONS
109	Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era. <i>Cancer</i> , 2014, 120, 2050-2059.	4.1	36
110	Deep MicroRNA sequencing reveals downregulation of miR-29a in neuroblastoma central nervous system metastasis. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 803-814.	2.8	21
111	Therapeutic Antibodies and Immunologic Conjugates. , 2014, , 508-518.e7.		2
112	Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti-CD22 3F8 monoclonal antibody. <i>Cancer</i> , 2013, 119, 2789-2795.	4.1	26
113	Early negative minimal residual disease in bone marrow after immunotherapy is less predictive of late or non-marrow relapse among patients with high-risk stage 4 neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2013, 60, E32-4.	1.5	9
114	Neuroblastoma: developmental biology, cancer genomics and immunotherapy. <i>Nature Reviews Cancer</i> , 2013, 13, 397-411.	28.4	632
115	Reply to L. Moreno et al. <i>Journal of Clinical Oncology</i> , 2013, 31, 650-651.	1.6	1
116	Recurrent pre-existing and acquired DNA copy number alterations, including focal TERT gains, in neuroblastoma central nervous system metastases. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 1150-1166.	2.8	27
117	Anti-GD2 antibody 3F8 and barley-derived (1- β)-D-glucan. <i>Oncolmmunology</i> , 2013, 2, e234024.6		30
118	Intraperitoneal radioimmunotherapy (RIT) for desmoplastic small round cell tumor (DSRCT): Initial results from a phase I trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 3033-3033.	1.6	5
119	In silico Driven Redesign of a Clinically Relevant Antibody for the Treatment of GD2 Positive Tumors. <i>PLoS ONE</i> , 2013, 8, e63359.	2.5	32
120	Activation of Peripheral-Blood Granulocytes Is Strongly Correlated With Patient Outcome After Immunotherapy With Anti-GD2 Monoclonal Antibody and Granulocyte-Macrophage Colony-Stimulating Factor. <i>Journal of Clinical Oncology</i> , 2012, 30, 426-432.	1.6	57
121	Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo. <i>Oncolmmunology</i> , 2012, 1, 477-486.	4.6	112
122	De Novo Engineering of a Human Cystathionine- β -Lyase for Systemic Methionine Depletion Cancer Therapy. <i>ACS Chemical Biology</i> , 2012, 7, 1822-1829.	3.4	32
123	A Three-Gene Expression Signature Model for Risk Stratification of Patients with Neuroblastoma. <i>Clinical Cancer Research</i> , 2012, 18, 2012-2023.	7.0	59
124	Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. <i>Journal of Clinical Investigation</i> , 2012, 122, 3260-3270.	8.2	190
125	Plerixafor plus granulocyte colony stimulating factor for autologous hematopoietic stem cell mobilization in patients with metastatic neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2012, 58, 469-471.	1.5	26
126	Anti-CD3-anti-GD2 bispecific antibody redirects T cell cytolytic activity to neuroblastoma targets. <i>Pediatric Blood and Cancer</i> , 2012, 59, 1198-1205.	1.5	70

#	ARTICLE	IF	CITATIONS
127	Murine Anti-GD2 Monoclonal Antibody 3F8 Combined With Granulocyte-Macrophage Colony-Stimulating Factor and 13- <i>Cis</i> -Retinoic Acid in High-Risk Patients With Stage 4 Neuroblastoma in First Remission. <i>Journal of Clinical Oncology</i> , 2012, 30, 3264-3270.	1.6	215
128	Association of Age at Diagnosis and Genetic Mutations in Patients With Neuroblastoma. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 1062.	7.4	379
129	The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma. <i>Cancer Cell</i> , 2012, 22, 117-130.	16.8	270
130	Intraperitoneal radioimmunotherapy (RIT) for desmoplastic small round cell tumor (DSRCT).. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS9595-TPS9595.	1.6	2
131	Two-compartment model of radioimmunotherapy delivered through cerebrospinal fluid. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 334-342.	6.4	11
132	Impact of minimal tumor burden on antibody response to vaccination. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 621-627.	4.2	14
133	Checkpoint kinase inhibitor synergizes with DNA-damaging agents in G_{1} checkpoint-defective neuroblastoma. <i>International Journal of Cancer</i> , 2011, 129, 1953-1962.	5.1	33
134	Successful Multifold Dose Escalation of Anti- G_{2} Monoclonal Antibody 3F8 in Patients With Neuroblastoma: A Phase I Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 1168-1174.	1.6	55
135	Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. <i>Journal of Neuro-Oncology</i> , 2010, 97, 409-418.	2.9	208
136	Small-Molecule Ligands of GD2 Ganglioside, Designed from NMR Studies, Exhibit Induced-Fit Binding and Bioactivity. <i>Chemistry and Biology</i> , 2010, 17, 183-194.	6.0	11
137	Whole Neuraxis Irradiation to Address Central Nervous System Relapse in High-Risk Neuroblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 849-854.	0.8	16
138	Hypothyroidism after ¹³¹ I-monoclonal antibody treatment of neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2010, 55, 76-80.	1.5	6
139	High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma. <i>Clinical Cancer Research</i> , 2010, 16, 1108-1118.	7.0	143
140	Interstitial Infusion of Glioma-Targeted Recombinant Immunotoxin 8H9scFv-PE38. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 1039-1046.	4.1	31
141	Analysis of GD2/GM2 synthase mRNA as a biomarker for small cell lung cancer. <i>Lung Cancer</i> , 2010, 67, 216-220.	2.0	6
142	Neuroblastoma: Therapeutic strategies for a clinical enigma. <i>Cancer Treatment Reviews</i> , 2010, 36, 307-317.	7.7	141
143	Reply to K. Satharasinghe et al. <i>Journal of Clinical Oncology</i> , 2009, 27, e235-e235.	1.6	2
144	Reducing Epitope Spread during Affinity Maturation of an Anti-Ganglioside GD2 Antibody. <i>Journal of Immunology</i> , 2009, 183, 5748-5755.	0.8	34

#	ARTICLE	IF	CITATIONS
145	Long-term Outcomes in Survivors of Neuroblastoma: A Report From the Childhood Cancer Survivor Study. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1131-1140.	6.3	153
146	Sensitivity of Surveillance Studies for Detecting Asymptomatic and Unsuspected Relapse of High-Risk Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 1041-1046.	1.6	70
147	A Pharmacokinetic Model for Radioimmunotherapy Delivered Through Cerebrospinal Fluid for the Treatment of Leptomeningeal Metastases. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1324-1331.	5.0	11
148	Chimeric Receptor mRNA Transfection as a Tool to Generate Antineoplastic Lymphocytes. <i>Human Gene Therapy</i> , 2009, 20, 51-61.	2.7	48
149	Monoclonal antibody therapies for solid tumors. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 341-353.	3.1	19
150	<i>KIR</i> and <i>HLA</i> Genotypes Are Associated with Disease Progression and Survival following Autologous Hematopoietic Stem Cell Transplantation for High-Risk Neuroblastoma. <i>Clinical Cancer Research</i> , 2009, 15, 7330-7334.	7.0	117
151	MicroRNA miR-29 Modulates Expression of Immunoinhibitory Molecule B7-H3: Potential Implications for Immune Based Therapy of Human Solid Tumors. <i>Cancer Research</i> , 2009, 69, 6275-6281.	0.9	238
152	Specific gene expression profiles and chromosomal abnormalities are associated with infant disseminated neuroblastoma. <i>BMC Cancer</i> , 2009, 9, 44.	2.6	26
153	Methionine depletion with recombinant methioninase: <i>In vitro</i> and <i>in vivo</i> efficacy against neuroblastoma and its synergism with chemotherapeutic drugs. <i>International Journal of Cancer</i> , 2009, 124, 1700-1706.	5.1	47
154	Reduced risk of secondary leukemia with fewer cycles of dose-intensive induction chemotherapy in patients with neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2009, 53, 17-22.	1.5	34
155	Hyperfractionated Low-Dose (21 Gy) Radiotherapy for Cranial Skeletal Metastases in Patients With High-Risk Neuroblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 1181-1186.	0.8	9
156	Management and outcome of stage 3 neuroblastoma. <i>European Journal of Cancer</i> , 2009, 45, 90-98.	2.8	39
157	Brain-sparing radiotherapy for neuroblastoma skull metastases. <i>Pediatric Blood and Cancer</i> , 2008, 50, 1163-1168.	1.5	15
158	Evaluation of widely consumed botanicals as immunological adjuvants. <i>Vaccine</i> , 2008, 26, 4860-4865.	3.8	55
159	Exploiting Gene Expression Profiling to Identify Novel Minimal Residual Disease Markers of Neuroblastoma. <i>Clinical Cancer Research</i> , 2008, 14, 7020-7027.	7.0	64
160	Prospective tracing of MLL-FRYL clone with low MEIS1 expression from emergence during neuroblastoma treatment to diagnosis of myelodysplastic syndrome. <i>Blood</i> , 2008, 111, 3802-3812.	1.4	14
161	INTRAPARENCHYMAL AND INTRATUMORAL INTERSTITIAL INFUSION OF ANTI-GLIOMA MONOCLONAL ANTIBODY 8H9. <i>Neurosurgery</i> , 2008, 63, 1166-1174.	1.1	17
162	Novel Markers of Subclinical Disease for Ewing Family Tumors from Gene Expression Profiling. <i>Clinical Cancer Research</i> , 2007, 13, 6978-6983.	7.0	64

#	ARTICLE	IF	CITATIONS
163	Phase I Study of Targeted Radioimmunotherapy for Leptomeningeal Cancers Using Intra-Ommaya 131I-I-3F8. <i>Journal of Clinical Oncology</i> , 2007, 25, 5465-5470.	1.6	121
164	WHOLE-BODY CLEARANCE KINETICS AND EXTERNAL DOSIMETRY OF 131I-3F8 MONOCLONAL ANTIBODY FOR RADIOIMMUNOTHERAPY OF NEUROBLASTOMA. <i>Health Physics</i> , 2007, 92, 33-39.	0.5	9
165	Disialoganglioside Directed Immunotherapy of Neuroblastoma. <i>Cancer Investigation</i> , 2007, 25, 67-77.	1.3	105
166	High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: Broad implications for immunotherapy. <i>Pediatric Blood and Cancer</i> , 2007, 48, 430-434.	1.5	19
167	Induction for high-risk neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2007, 49, 221-223.	1.5	6
168	Liver involvement in neuroblastoma: The memorial Sloan-Kettering experience supports treatment reduction in young patients. <i>Pediatric Blood and Cancer</i> , 2006, 46, 278-284.	1.5	14
169	FCGR2A Polymorphism Is Correlated With Clinical Outcome After Immunotherapy of Neuroblastoma With Anti-GD2 Antibody and Granulocyte Macrophage Colony-Stimulating Factor. <i>Journal of Clinical Oncology</i> , 2006, 24, 2885-2890.	1.6	129
170	Irinotecan Plus Temozolomide for Relapsed or Refractory Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 5271-5276.	1.6	121
171	Rituximab therapy of lymphoma is enhanced by orally administered (1 α ’3),(1 α ’4)-d- β -glucan. <i>Leukemia Research</i> , 2005, 29, 679-683.	0.8	75
172	Long-term complications in survivors of advanced stage neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2005, 45, 324-332.	1.5	149
173	Prognostic value of MYCN and ID2 overexpression in neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2005, 45, 909-915.	1.5	20
174	EMP3, a Myelin-Related Gene Located in the Critical 19q13.3 Region, Is Epigenetically Silenced and Exhibits Features of a Candidate Tumor Suppressor in Glioma and Neuroblastoma. <i>Cancer Research</i> , 2005, 65, 2565-2571.	0.9	154
175	Complement-Mediated Mechanisms in Anti-GD2 Monoclonal Antibody Therapy of Murine Metastatic Cancer. <i>Cancer Research</i> , 2005, 65, 10562-10568.	0.9	120
176	Neuroblastoma from Genetic Profiles to Clinical Challenge. <i>New England Journal of Medicine</i> , 2005, 353, 2215-2217.	27.0	29
177	Radioimmunotargeting of Human Rhabdomyosarcoma Using Monoclonal Antibody 8H9. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2005, 20, 534-546.	1.0	35
178	Immunology and Immunotherapy. , 2005, , 223-242.		4
179	Camptothecin Analogs (Irinotecan or Topotecan) plus High-Dose Cyclophosphamide as Preparative Regimens for Antibody-Based Immunotherapy in Resistant Neuroblastoma. <i>Clinical Cancer Research</i> , 2004, 10, 84-87.	7.0	40
180	Clustering of Gene Hypermethylation Associated With Clinical Risk Groups in Neuroblastoma. <i>Journal of the National Cancer Institute</i> , 2004, 96, 1208-1219.	6.3	119

#	ARTICLE	IF	CITATIONS
181	Treatment of Neuroblastoma Meningeal Carcinomatosis with Intrathecal Application of β -Emitting Atomic Nanogenerators Targeting Disialo-Ganglioside GD2. <i>Clinical Cancer Research</i> , 2004, 10, 6985-6992.	7.0	52
182	In Vitro and in Vivo Cytotoxic Activities of Recombinant Immunotoxin 8H9(Fv)-PE38 against Breast Cancer, Osteosarcoma, and Neuroblastoma. <i>Cancer Research</i> , 2004, 64, 1419-1424.	0.9	51
183	Reduction From Seven to Five Cycles of Intensive Induction Chemotherapy in Children With High-Risk Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2004, 22, 4888-4892.	1.6	119
184	Mechanism by Which Orally Administered β -1,3-Glucans Enhance the Tumoricidal Activity of Antitumor Monoclonal Antibodies in Murine Tumor Models. <i>Journal of Immunology</i> , 2004, 173, 797-806.	0.8	419
185	Characteristics of Stem Cells from Human Neuroblastoma Cell Lines and in Tumors. <i>Neoplasia</i> , 2004, 6, 838-845.	5.3	200
186	Favorable-Biology Neuroblastoma Presenting With Leptomeningeal Metastases?. <i>Journal of Pediatric Hematology/Oncology</i> , 2004, 26, 703-705.	0.6	4
187	Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, ^{225}Ac -HuM195, in nonhuman primates. <i>Journal of Nuclear Medicine</i> , 2004, 45, 129-37.	5.0	79
188	Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2. <i>Journal of Nuclear Medicine</i> , 2004, 45, 867-77.	5.0	41
189	Neuroblastoma in adolescents and adults: The Memorial Sloan-Kettering experience. <i>Medical and Pediatric Oncology</i> , 2003, 41, 508-515.	1.0	80
190	Tumor lysis syndrome, neuroblastoma, and correlation between serum lactate dehydrogenase levels and MYCN-amplification. <i>Medical and Pediatric Oncology</i> , 2003, 41, 80-82.	1.0	25
191	Evolving significance of prognostic markers associated with new treatment strategies in neuroblastoma. <i>Cancer Letters</i> , 2003, 197, 119-124.	7.2	25
192	Anti-Idiotypic Antibody Facilitates scFv Chimeric Immune Receptor Gene Transduction and Clonal Expansion of Human Lymphocytes for Tumor Therapy. <i>Hybridoma</i> , 2003, 22, 209-218.	0.4	20
193	Quantitation of GD2 Synthase mRNA by Real-Time Reverse Transcriptase Polymerase Chain Reaction: Clinical Utility in Evaluating Adjuvant Therapy in Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2003, 21, 1087-1093.	1.6	55
194	Impact of Metaiodobenzylguanidine Scintigraphy on Assessing Response of High-Risk Neuroblastoma to Dose-Intensive Induction Chemotherapy. <i>Journal of Clinical Oncology</i> , 2003, 21, 1082-1086.	1.6	60
195	Curability of Recurrent Disseminated Disease After Surgery Alone for Local-Regional Neuroblastoma Using Intensive Chemotherapy and Anti-GD2 Immunotherapy. <i>Journal of Pediatric Hematology/Oncology</i> , 2003, 25, 515-519.	0.6	21
196	Early Molecular Response of Marrow Disease to Biologic Therapy Is Highly Prognostic in Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2003, 21, 3853-3858.	1.6	49
197	Anti-Idiotypic Antibody as the Surrogate Antigen for Cloning scFv and its Fusion Proteins. <i>Hybridoma</i> , 2002, 21, 433-443.	0.4	7
198	Disialoganglioside G _{D2} and a novel tumor antigen: Potential targets for immunotherapy of desmoplastic small round cell tumor. <i>Medical and Pediatric Oncology</i> , 2002, 39, 547-551.	1.0	54

#	ARTICLE	IF	CITATIONS
199	Quantitation of GD2 synthase mRNA by real-time reverse transcription-polymerase chain reaction. <i>Cancer</i> , 2002, 94, 3042-3048.	4.1	22
200	Evolving significance of prognostic markers associated with treatment improvement in patients with Stage 4 neuroblastoma. <i>Cancer</i> , 2002, 94, 2756-2765.	4.1	28
201	Chronic neuroblastoma. <i>Cancer</i> , 2002, 95, 1366-1375.	4.1	24
202	Orally administered β -glucans enhance anti-tumor effects of monoclonal antibodies. <i>Cancer Immunology, Immunotherapy</i> , 2002, 51, 557-564.	4.2	160
203	Novel regions of allelic imbalance identified by genome-wide analysis of neuroblastoma. <i>Cancer Research</i> , 2002, 62, 1761-7.	0.9	17
204	Oral (1 \rightarrow 3),(1 \rightarrow 4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma. <i>Clinical Cancer Research</i> , 2002, 8, 1217-23.	7.0	75
205	MONOCLONAL ANTIBODY-BASED THERAPY OF NEUROBLASTOMA. <i>Hematology/Oncology Clinics of North America</i> , 2001, 15, 853-864.	2.2	36
206	Phase II Trial of the Anti-GD2 Monoclonal Antibody 3F8 and Granulocyte-Macrophage Colony-Stimulating Factor for Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2001, 19, 4189-4194.	1.6	192
207	Hyperfractionated Low-Dose Radiotherapy for High-Risk Neuroblastoma After Intensive Chemotherapy and Surgery. <i>Journal of Clinical Oncology</i> , 2001, 19, 2821-2828.	1.6	119
208	Immunomagnetic Purging of Ewing's Sarcoma From Blood and Bone Marrow: Quantitation by Real-Time Polymerase Chain Reaction. <i>Journal of Clinical Oncology</i> , 2001, 19, 3649-3659.	1.6	25
209	Antibody-based diagnostic and therapeutic innovations for human cancer. <i>Comprehensive Therapy</i> , 2001, 27, 183-194.	0.2	1
210	Survival analysis of clinical, pathologic, and genetic features in neuroblastoma presenting as locoregional disease. <i>Cancer</i> , 2001, 91, 435-442.	4.1	23
211	Neuroblastoma metastatic to the central nervous system. <i>Cancer</i> , 2001, 91, 1510-1519.	4.1	131
212	Disialoganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma. <i>Medical and Pediatric Oncology</i> , 2001, 36, 194-196.	1.0	33
213	Detection of microscopic disease: Comparing histology, immunocytology, and RT-PCR of tyrosine hydroxylase, GAGE, and MAGE. <i>Medical and Pediatric Oncology</i> , 2001, 36, 210-212.	1.0	23
214	N7: A novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. <i>Medical and Pediatric Oncology</i> , 2001, 36, 227-230.	1.0	114
215	N7: A novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. <i>Medical and Pediatric Oncology</i> , 2001, 36, 227-230.	1.0	1
216	Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors. <i>Medical and Pediatric Oncology</i> , 2000, 35, 468-474.	1.0	64

#	ARTICLE	IF	CITATIONS
217	Laser-capture microdissected Schwannian and neuroblastic cells in stage 4 neuroblastomas have the same genetic alterations. <i>Medical and Pediatric Oncology</i> , 2000, 35, 534-537.	1.0	11
218	Prognostic significance of GAGE detection in bone marrows on survival of patients with metastatic neuroblastoma. <i>Medical and Pediatric Oncology</i> , 2000, 35, 632-634.	1.0	25
219	Correlation of anti-idiotypic network with survival following anti-GD2 monoclonal antibody 3F8 therapy of stage 4 neuroblastoma. <i>Medical and Pediatric Oncology</i> , 2000, 35, 635-637.	1.0	22
220	Targeted radioimmunotherapy for leptomeningeal cancer using 131I-3F8. <i>Medical and Pediatric Oncology</i> , 2000, 35, 716-718.	1.0	43
221	Monoclonal antibody-based therapy for neuroblastoma. <i>Current Oncology Reports</i> , 2000, 2, 547-553.	4.0	18
222	Comparison of in vitro antibody-targeted cytotoxicity using mouse, rat and human effectors. <i>Cancer Immunology, Immunotherapy</i> , 2000, 49, 259-266.	4.2	61
223	Surface Antigen Expression and Complement Susceptibility of Differentiated Neuroblastoma Clones. <i>American Journal of Pathology</i> , 2000, 156, 1085-1091.	3.8	27
224	Clinical Categories of Neuroblastoma Are Associated with Different Patterns of Loss of Heterozygosity on Chromosome Arm 1p. <i>Journal of Molecular Diagnostics</i> , 2000, 2, 37-46.	2.8	46
225	Prognostic significance of GAGE detection in bone marrows on survival of patients with metastatic neuroblastoma. <i>Medical and Pediatric Oncology</i> , 2000, 35, 632-634.	1.0	1
226	Oral Etoposide for Refractory and Relapsed Neuroblastoma. <i>Journal of Clinical Oncology</i> , 1999, 17, 3221-3225.	1.6	55
227	Treatment of neoplastic meningeal xenografts by intraventricular administration of an antiganglioside monoclonal antibody, 3F8. , 1999, 82, 538-548.		12
228	Detection of neuroblastoma in bone marrow by immunocytology: Is a single marrow aspirate adequate?. , 1999, 32, 84-87.		12
229	Synovial sarcoma mimicking desmoplastic small round-cell tumor: Critical role for molecular diagnosis. , 1999, 32, 97-101.		21
230	Intrathecal Administration of an Anti-Ganglioside Antibody Results in Specific Accumulation Within Meningeal Neoplastic Xenografts in Nude Rats. <i>Journal of Immunotherapy</i> , 1999, 22, 114-123.	2.4	10
231	Title>Additive cytotoxicity of different monoclonal antibody-cobra venom factor conjugates for human neuroblastoma cells. <i>Immunobiology</i> , 1997, 197, 444-459.	1.9	30
232	Pharmacokinetics and acute toxicology of intraventricular 131 I-monoclonal antibody targeting disialoganglioside in non-human primates. <i>Journal of Neuro-Oncology</i> , 1997, 35, 101-112.	2.9	18
233	Comparison of the targeting characteristics of various radioimmunoconjugates for radioimmunotherapy of neuroblastoma: Dosimetry calculations incorporating cross-organ beta doses. <i>Nuclear Medicine and Biology</i> , 1996, 23, 1-8.	0.6	25
234	Targeting of small-cell lung cancer using the anti-GD2 ganglioside monoclonal antibody 3F8: A pilot trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1996, 23, 145-149.	2.1	49

#	ARTICLE	IF	CITATIONS
235	Kinetics of primary tumor regression with chemotherapy: Implications for the timing of surgery. <i>Annals of Surgical Oncology</i> , 1996, 3, 521-525.	1.5	35
236	Increased intellectual functioning in children with Neuroblastoma. <i>Child Neuropsychology</i> , 1996, 2, 77-82.	1.3	3
237	Major histocompatibility proteins, anti-Hu antibodies, and paraneoplastic encephalomyelitis in neuroblastoma and small cell lung cancer. <i>Cancer</i> , 1995, 75, 99-109.	4.1	159
238	Antibody-independent phagocytosis of tumor cells by human monocyte-derived macrophages cultured in recombinant macrophage colony-stimulating factor. <i>Cancer Immunology, Immunotherapy</i> , 1995, 41, 46-52.	4.2	5
239	Stage 4 neuroblastoma diagnosed at more than 1 year of age: Gross total resection and clinical outcome. <i>Journal of Pediatric Surgery</i> , 1994, 29, 1162-1166.	1.6	76
240	Disialoganglioside GD2 anti-idiotypic monoclonal antibodies. <i>International Journal of Cancer</i> , 1993, 54, 499-505.	5.1	48
241	Preferential amplification of the paternal allele of the Nâ€“myc gene in human neuroblastomas. <i>Nature Genetics</i> , 1993, 4, 191-194.	21.4	65
242	A novel O-acetylated ganglioside detected by anti-GD2 monoclonal antibodies. <i>International Journal of Cancer</i> , 1992, 50, 197-201.	5.1	31
243	Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas. <i>Cancer</i> , 1992, 70, 633-638.	4.1	97
244	Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas. , 1992, 70, 633.		3
245	High-dose melphalan with 6-hydroxydopamineâ€“purged autologous bone marrow transplantation for poor-risk neuroblastoma. <i>Cancer</i> , 1991, 68, 242-247.	4.1	20
246	Autografting with bone marrow exposed to multiple courses of very high dose cyclophosphamide in vivo and to 4-hydroperoxycyclophosphamide in vitro. <i>Medical and Pediatric Oncology</i> , 1990, 18, 454-458.	1.0	7
247	Dose-intensive use of cyclophosphamide in ablation of neuroblastoma. <i>Cancer</i> , 1990, 66, 1095-1100.	4.1	49
248	In Vitro Chemosensitivity of Two Ewing's Sarcoma Cell Lines: Implication for Autologous Bone Marrow Transplantation. <i>Cancer Investigation</i> , 1989, 7, 411-416.	1.3	10
249	Complete Tumor Ablation With Iodine 131-Radiolabeled Disialoganglioside GD2-Specific Monoclonal Antibody Against Human Neuroblastoma Xenografted in Nude Mice ²³ . <i>Journal of the National Cancer Institute</i> , 1986, 77, 739-745.	6.3	102